Galectin (GALT) Misses Q3 EPS by 2c; Updates on GR-MD-02 Phase 1 Cohort 1
Tweet Send to a Friend
Galectin (NASDAQ: GALT) reported Q3 EPS of ($0.22), $0.02 worse than the analyst estimate of ($0.20).
Galectin reported that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Galectin reported that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE